DMAC

DiaMedica Therapeutics Inc.

2.32 USD
-0.07 (-2.93%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

DiaMedica Therapeutics Inc. stock is down -24.18% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 12 June’s closed higher than May.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.